Results

Total Results: 2,208 records

Showing results for "drug".

1801. Treatment Strategies for Women With Coronary Artery Disease: Future Research Needs (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/cad-women-treatment-future_research.pdf
      February 01, 2013 - What are the significant safety concerns associated with each treatment strategy (e.g., adverse drug … What are the significant safety concerns associated with each treatment strategy (e.g., adverse drug … What are the significant safety concerns associated with each treatment strategy (e.g., adverse drug … KQ 1c considers the safety concerns associated with each treatment strategy (e.g., adverse drug reactions … Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery

1802. Data Points 14: Use of Endocrine Therapy (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/dcis-endocrine-therapy_research.pdf
      August 01, 2012 - therapy use over a five-year period for newly diagnosed women, because event data from the Medicare drug

1803. Dispostion of Comments Report for Child and Adolescent Exposure to Trauma (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/trauma-child-interventions_disposition-comments.pdf
      February 11, 2013 - Dispostion of Comments Report for Child and Adolescent Exposure to Trauma Source: http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and- reports/?pageaction=displayproduct&productID=1383 Published Online: February 11, 2013 Comparative Effectiveness Research Review Disposition of Comments Report …

1804. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/autism-adolescents_research-protocol.pdf
      March 29, 2011 - Food and Drug Administration (FDA)-approved medications for the treatment of irritability in ASD: risperidone … language, skills, or behaviors - Increases in or worsening of comorbid symptoms - Adverse reactions to drug

1805. Evidence Summary: Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-221-copd-evidence-summary_0.pdf
      October 01, 2019 - Current drug treatment, chronic and acute. Clin Chest Med. 2014 Mar;35(1):177-89.

1806. Assessing the Impact of Indexing Performance Measure Codes on the Perceived Value of EPC Reports to Health Systems (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-assessing-impact.pdf
      September 01, 2018 - target high-modifiable medication risk patients including home-visitations, telephonic and e-consults drug

1807. Childhood Obesity Prevention Programs: A Comparative Effectiveness Review and Meta-Analysis | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/obesity-child/research-protocol
      December 01, 2019 - Cell phone[tiab] Telephone[tiab] telemedicine[mh] Cure[tiab] Medication[tiab] Drug

1808. Title (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/obesity-child_research-protocol.pdf
      March 31, 2010 - House[tiab] Meal[tiab] Meals[tiab] Mother[tiab] Mothers[tiab] Cure[tiab] Medication[tiab] Drug

1809. Comparative Effectiveness of Interventions for Adolescents and Young Adults With Autism Spectrum Disorders | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/autism-adolescents/research-protocol
      December 01, 2019 - Food and Drug Administration (FDA)-approved medications for the treatment of irritability in ASD: risperidone … language, skills, or behaviors Increases in or worsening of comorbid symptoms Adverse reactions to drug

1810. Medical Therapies for Locally Advanced Gastric Adenocarcinoma | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/gastric-cancers/protocol
      February 01, 2025 - ., National Institutes of Health [NIH], Agency for Healthcare Research and Quality [AHRQ], Food and Drug … ipilimumab OR nivolumab OR opdivo OR pembrolizumab OR keytruda OR sintilimab OR tecentriq OR yervoy) 'drug

1811. Psoriasis-Chronic Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_executive.pdf
      November 01, 2012 - etanercept, and adalimumab), and one anti-IL 12/23 agent (ustekinumab) have approval from the Food and Drug … agents concluded a difference in efficacy, suggesting heterogeneity within the class and indicating drug … and therefore do not make between-class comparisons, rather limit comparisons with the individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug

1812. Evidence Report on the (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/antidepressants-update_research-protocol.pdf
      July 13, 2011 - , continuation phase) or recurrence (i.e., maintenance phase) when a patient 1) continues the drug … medications with new formulations (such as an extended release formulation) are approved by the Food and Drug … Administration (FDA) through an application called a supplemental new drug application (sNDA). … interest is whether response or remission can be maintained if patients who have responded to one drug … If fewer than three head-to-head trials are available for any drug comparison, we will compute indirect

1813. Disposition of Comment Report for Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/wireless-motility-capsule_disposition-comments.pdf
      May 20, 2013 - Cisapride had benefit in prokinetic activity, but drug interactions limited its value. and so on... … It is physicians rather than patients who decide about using prokinetics or any other drug.

1814. Chronic-Urinary-Retention Research (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/chronic-urinary-retention_research.pdf
      September 01, 2014 - Patients with acute or transient retention attributed to drug side effects, medical or surgical procedures … Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment … /prostaglandin E2; CI = confidence interval; NR = not reported; RR=risk ratio * Uterine leiomyoma, drug … Reductase Inhibition Combined with an Alpha Blocker Urinary Retention|Benign Prostatic Hyperplasia Drug

1815. Evidence Map on Home and Community Based Services | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/evidence-map/protocol
      September 01, 2023 - Food and Drug Administration, ClinicalTrials.gov, Health Canada, U.K.

1816. Health Information Exchange (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/health-information-exchange_executive.pdf
      December 01, 2015 - Am Health Drug Benefits. 2011;4(4):207-15. PMID: 25126351. 6. … Am Health Drug Benefits. 2012;5(6):333-40. PMID: 24991331. 20.

1817. A Systematic Review of Postpartum Home Blood Pressure Monitoring, Postpartum Treatment of Hypertensive Disorders of Pregnancy, and Peripartum Magnesium Sulfate Regimens for Preeclampsia With Severe Features (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/product/pdf/hypertensive-disorders-pregnancy-protocol-amendment.pdf
      April 20, 2022 - Other clinically important adverse events* (e.g., hypotension, neuromuscular blockade) o Adverse drug … health disparities • Magnesium related toxicity • Other clinically important adverse events • Adverse drug

1818. Postpartum Home Blood Pressure Monitoring, Postpartum Treatment of Hypertensive Disorders of Pregnancy, and Peripartum Magnesium Sulfate Regimens for Preeclampsia With Severe Features | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/hypertensive-disorders-pregnancy/protocol
      April 01, 2022 - Other clinically important adverse events* (e.g., hypotension, neuromuscular blockade) Adverse drug … health disparities Magnesium related toxicity Other clinically important adverse events Adverse drug

1819. Diagnosis and Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/chronic-fatigue_executive.pdf
      July 01, 2016 - Food and Drug Administration (FDA) for the treatment of ME/CFS, but several have been used “off label … A controlled clinical trial with a specifically configured RNA drug, poly(I) midline dot poly(C12U)

1820. Breast-Cancer-Imaging Technical-Brief (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/breast-cancer-imaging_technical-brief.pdf
      October 01, 2014 - Food and Drug Administration (FDA) approval status, need for additional equipment (e.g., contrast agents … Food and Drug Administration; FDG = fluorodeoxyglucose; FES = fluoroestradiol; FLT = fluorothymidine … Food and Drug Administration. What are the Radiation Risks from CT? U.S. … Found 1 exp Diagnostic Imaging 1748368 2 exp Breast Neoplasms/dh, dt, pc, rt, su, th [Diet Therapy, Drug … Tumor regression by means of magnetic drug targeting. Nanomedicine (Lond). 2009 Dec;4(8):875-82.